Report cover image

Retinal Disease Therapeutics Market Size, Share, Growth and Global Industry Analysis By Type & Application, Regional Insights and Forecast to 2024-2032

Publisher Fortune Business Insights Pvt. Ltd.
Published Jan 01, 2025
Length 116 Pages
SKU # FOB19472455

Description

Retinal Disease Therapeutics Market Size, Share, Growth and Global Industry Analysis By Type & Application, Regional Insights and Forecast to 2024-2032



Growth Factors of Retinal Disease Therapeutics Market

The Retinal Disease Therapeutics Market size was valued at USD 11.04 billion in 2023, and the market is now projected to grow to 21.31 USD billion by 2032, exhibiting a CAGR of 8.6% during the forecast period of 2023-2030.

The pandemic has been anticipated to be a bane for the entire industrial developments of various market and fields. This has affected the overall supply and demand chains of the particular market. As a result of the government's lockdown and other steps to stop the coronavirus from spreading, all supply activities were postponed, which decreased the amount of product related to this domain. These factors affected the Retinal Disease Therapeutics Market growth.

This has been recorded to be the most effective driving factor for this particular product market. There are very few companies in the global market for treatments for retinal diseases, and the vendor environment is now very consolidated. These particular growth driving factors have been recorded to attribute the Retinal Disease Therapeutics Market share. Regeneron Pharmaceuticals, Inc.'s Eylea is a well-known treatment that has been authorized for serious retinal conditions such AMD, DME, and RVO. Due to the product's substantial revenue, the company's standing in the ophthalmology sector has improved.

It is necessary for a product market to walk with the trends in order to increases its lucracy and profits in shares and all over revenue. The incidence of retinal disorders such diabetic retinopathy and diabetic macular edema is on the rise in emerging nations due to the growing prevalence of diabetes. Throughout the projected period, the rise of skilled experts worldwide who specialize in treating retinal diseases is anticipated to support the market expansion for retinal disease treatments.

Comprehensive Analysis of Retinal Disease Therapeutics Market

The segmentation of this particular market has been divided and then further subdivided into various categories. The market for retinal illness treatments includes a number of disease indications, including diabetic retinopathy, retinal vein occlusion (RVO), diabetic macular edema (DME), and macular degeneration (MD). These particular segmentations have been categorized into such groups so that their attribution to the overall revenue systems are properly recorded studied so as to determine which is the leading and most beneficial segment of all.

This particular region has augmented a lot in the past few years in this particular product market. North America accounted for millions of dollars in revenue. The dominance is due to the USFDA's positive signal for the approval of new anti-VEGF treatments in the US, the pharmaceutical companies' extensive ophthalmology portfolio, and their ongoing clinical trials for retinal disorders. This specific region held the biggest revenue share. The region is expected to maintain a significant proportion during the projected period.

Global markets are fiercely competitive and highly fragmented. Due to their creative packaging solutions, a few group of large market companies hold a fair amount of market share. Some of the major Companies includes Merck & Co., Inc. (U.S.), Novartis AG (Switzerland), Allergan plc (Ireland), F. Hoffmann-La Roche AG (Switzerland), Regeneron Pharmaceuticals, Inc. (United States), and Santen Pharmaceutical Co., Ltd. (Japan).

In April 2021, This particular company has attributed the market growth in terms of revenue and shares system. Clearside Biomedical, Inc. (Nasdaq: CLSD), a biopharmaceutical company that is transforming the delivery of therapies to the back of the eye through the suprachoroidal space, announced today that Santen Pharmaceutical Co., Ltd. and Arctic Vision. This specific development of this particular product market player has been recorded to be a boon for the market revenue and share systems altogether.

Segmentation Table

ATTRIBUTE DETAILS

By Disease Indication · Macular Degeneration

· Diabetic Retinopathy

· Diabetic Macular Edema

· Retinal Vein Occlusion

· Others

By Distribution Channel · Hospital Pharmacy

· Retail Pharmacy

· Others

By Geography · North America (USA and Canada)

· Europe (UK, Germany, France, Italy, Spain, Scandinavia, and Rest of Europe)

· Asia Pacific (Japan, China, India, Australia, Southeast Asia, and Rest of Asia Pacific)

· Latin America (Brazil, Mexico, Rest of Latin America)

· Middle East & Africa (GCC, South Africa, Rest of Middle East & Africa)

Table of Contents

116 Pages
1. Introduction
1.1. Research Scope
1.2. Market Segmentation
1.3. Research Methodology
1.4. Definitions and Assumptions
2. Executive Summary
3. Market Dynamics
3.1. Market Drivers
3.2. Market Restraints
3.3. Market Opportunities
4. Key Insights
5. 4.1 Recent industry developments such as mergers & acquisitions
6. 4.2 Regulatory scenario for key countries
7. 4.3 Prevalence of Key Retinal Diseases, in Major Countries
8. 4.4 Pipeline Analysis
9. 4.5 Patent Snapshot
10. 5. Global Retinal Disease Therapeutics Market Analysis, Insights and Forecast, 2015-2026
11. 5.1. Key Findings / Summary
12. 5.2 Market Analysis, Insights and Forecast – By Disease Indication
13. 5.2.1 Macular Degeneration
14. 5.2.2 Diabetic Macular Edema
15. 5.2.3 Diabetic Retinopathy
16. 5.2.4 Retinal Vein Occlusion
17. 5.2.5 Others
18. 5.3. Market Analysis, Insights and Forecast – By End User
19. 5.3.1 Hospital Pharmacy
20. 5.3.2 Retail Pharmacy
21. 5.3.3 Others
22. 5.4. Market Analysis, Insights and Forecast – By Region
23. 5.4.1 North America
24. 5.4.2 Europe
25. 5.4.3 Asia Pacific
26. 5.4.4 Latin America
27. 5.4.5 Middle East & Africa
28. 6. North America Retinal Disease Therapeutics Market Analysis, Insights and Forecast, 2015-2026
29. 6.1. Key Findings / Summary
30. 6.2. Market Analysis – By Disease Indication
31. 6.2.1 Macular Degeneration
32. 6.2.2 Diabetic Macular Edema
33. 6.2.3 Diabetic Retinopathy
34. 6.2.4 Retinal Vein Occlusion
35. 6.2.5 Others
36. 6.3. Market Analysis – By End User
37. 6.3.1 Hospital Pharmacy
38. 6.3.2 Retail Pharmacy
39. 6.3.3 Others
40. 6.4. Market Analysis – By Country
41. 6.4.1 U.S.
42. 6.4.2 Canada
43. 7. Europe Retinal Disease Therapeutics Market Analysis, Insights and Forecast, 2015-2026
44. 7.1. Key Findings / Summary
45. 7.2. Market Analysis – By Disease Indication
46. 7.2.1 Macular Degeneration
47. 7.2.2 Diabetic Macular Edema
48. 7.2.3 Diabetic Retinopathy
49. 7.2.4 Retinal Vein Occlusion
50. 7.2.5 Others
51. 7.3. Market Analysis – By End User
52. 7.3.1 Hospital Pharmacy
53. 7.3.2 Retail Pharmacy
54. 7.3.3 Others
55. 7.4. Market Analysis – By Country
56. 7.4.1 Germany
57. 7.4.2 U.K.
58. 7.4.3 France
59. 7.4.4 Italy
60. 7.4.5 Spain
61. 7.4.6 Scandinavia
62. 7.4.7 Rest of Europe
63. 8. Asia Pacific Retinal Disease Therapeutics Market Analysis, Insights and Forecast, 2015-2026
64. 8.1. Key Findings / Summary
65. 8.2. Market Analysis – By Disease Indication
66. 8.2.1 Macular Degeneration
67. 8.2.2 Diabetic Macular Edema
68. 8.2.3 Diabetic Retinopathy
69. 8.2.4 Retinal Vein Occlusion
70. 8.2.5 Others
71. 8.3. Market Analysis – By End User
72. 8.3.1 Hospital Pharmacy
73. 8.3.2 Retail Pharmacy
74. 8.3.3 Others
75. 8.4. Market Analysis – By Country
76. 8.4.1 India
77. 8.4.2 China
78. 8.4.3 Japan
79. 8.4.4 Australia
80. 8.4.5 Southeast Asia
81. 8.4.6 Rest of Asia Pacific
82. 9. Latin America Retinal Disease Therapeutics Market Analysis, Insights and Forecast, 2015-2026
83. 9.1. Key Findings / Summary
84. 9.2. Market Analysis – By Type
85. 9.2.1 Macular Degeneration
86. 9.2.2 Diabetic Macular Edema
87. 9.2.3 Diabetic Retinopathy
88. 9.2.4 Retinal Vein Occlusion
89. 9.2.5 Others
90. 9.3. Market Analysis – By End User
91. 9.3.1 Hospital Pharmacy
92. 9.3.2 Retail Pharmacy
93. 9.3.3 Others
94. 9.4. Market Analysis – By Country
95. 9.4.1 Brazil
96. 9.4.2 Mexico
97. 9.4.3 Rest of Latin America
98. 10. Middle East &Africa Retinal Disease Therapeutics Market Analysis, Insights and Forecast,2015-2026
99. 10.1. Key Findings / Summary
100. 10.2. Market Analysis – By Disease Indication
101. 10.2.1 Macular Degeneration
102. 10.2.2 Diabetic Macular Edema
103. 10.2.3 Diabetic Retinopathy
104. 10.2.4 Retinal Vein Occlusion
105. 10.2.5 Others
106. 10.3. Market Analysis – By End User
107. 10.3.1 Hospital Pharmacy
108. 10.3.2 Retail Pharmacy
109. 10.3.3 Others
110. 10.4. Market Analysis – By Country
111. 10.4.1 GCC
112. 10.4.2 South Africa
113. 10.4.3 Rest of Middle East & Africa
114. 11. Competitive Analysis
115. 11.1. Key Industry Developments
116. 11.2. Global Market Share Analysis (2018)
117. 11.3. Competition Dashboard
118. 11.4. Comparative Analysis –Major Players
119. 11.5. Company Profiles (Overview,Products & services, SWOT analysis, Recent developments, strategies,financials (based on availability))
120. 11.5.1 Merck& Co., Inc.
121. 11.5.2 Novartis AG
122. 11.5.3 Allergan plc
123. 11.5.4 Regeneron Pharmaceuticals, Inc.
124. 11.5.5 Santen Pharmaceutical Co., Ltd.
125. 11.5.6 F.Hoffmann-La Roche AG
126. 12. Strategic Recommendations

Pricing

Currency Rates
How Do Licenses Work?

How Do Licenses Work?

The primary function of a report license is to define how many people within a company are authorized to use the purchased report. This is separate to how a report might be delivered. Unless specifically identified otherwise, the purchase option is Single User. Below is a helpful description of that license, along with a sampling of others most commonly offered.

  • This license allows only one user to have access to and to use/read the report. It is not one user at a time or one user group; it is an individual who will be reading and utilizing the report.

  • This license allows for the entire purchasing company to read and use the report. This is the license level that would allow for a report to be placed on an internal company shared drive for access by all employees of that direct company. This license does not extend to parent or sister company use.

  • This license is designed to allow an entire department within a company full access to a report. The departmental license is a great option for companies that have more than one location and the department is spread out all over the country/world

  • This license is for companies that have one location where they want the report to be accessible by all employees within that physical location.

  • This is the most flexible of the licensing options. Some publishers will allow you to get a license for a preset number of people (typically 5). These licenses are ideal for small work groups.

License options are at the discretion of each publisher. As such, not all licenses indicated above are available for every product. If you are uncertain of the best license for your needs or would like a license that is not proactively available, please contact us and we will be happy to assist.

Head shot

Questions or Comments?

Our team has the ability to search within reports to verify it suits your needs. We can also help maximize your budget by finding sections of reports you can purchase.
Chat Now
Contact Us